Literature DB >> 23872376

Comparison of the ex vivo receptor occupancy profile of ketamine to several NMDA receptor antagonists in mouse hippocampus.

Brian Lord1, Cindy Wintmolders, Xavier Langlois, Leslie Nguyen, Tim Lovenberg, Pascal Bonaventure.   

Abstract

NMDA receptor antagonists, particularly these targeting the GluN2B subunit are of therapeutic interest for the treatment of severe mood disorders. The receptor occupancy profiles of several NMDA receptor antagonists (30 mg/kg, s.c.) were compared in mouse hippocampus by ex vivo autoradiography using [(3)H]MK-801, a non-selective NMDA channel blocker, and [(3)H]ifenprodil a selective GluN2B antagonist. Subcutaneous administration of ketamine ((RS)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone) and memantine (3,5-dimethyladamantan-1-amine) inhibited [(3)H]MK-801 but not [(3)H]ifenprodil binding in mouse hippocampus. Ketamine reached maximal occupancy of [(3)H]MK-801 binding sites after 15 min and rapidly cleared from the brain with no significant level of occupancy measured at the 1h time point. Memantine significantly occupied [(3)H]MK-801 binding sites throughout the 6h time course. The selective GluN2B antagonist CP101,606 ((1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol) and Ro 25-6981 ((αR,βS)-α-(4-Hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidinepropanol maleate) inhibited [(3)H]ifenprodil but not [(3)H]MK-801 binding and significant levels of occupancy (above 50%) were measured throughout the 6h time course. These data highlight the unique quick pulse target engagement profile of ketamine compared to other NMDA receptor antagonists.
© 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoradiography; GluN2B; Ketamine; NMDA; Receptor occupancy

Mesh:

Substances:

Year:  2013        PMID: 23872376     DOI: 10.1016/j.ejphar.2013.06.028

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  Increasing doses of ketamine curtail antidepressant responses and suppress associated synaptic signaling pathways.

Authors:  Ji-Woon Kim; Lisa M Monteggia
Journal:  Behav Brain Res       Date:  2019-11-21       Impact factor: 3.332

Review 2.  Antidepressant Actions of Ketamine Mediated by the Mechanistic Target of Rapamycin, Nitric Oxide, and Rheb.

Authors:  Maged M Harraz; Solomon H Snyder
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

Review 3.  A brief history of the development of antidepressant drugs: from monoamines to glutamate.

Authors:  Todd M Hillhouse; Joseph H Porter
Journal:  Exp Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.157

4.  Effects of Mg2+ on recovery of NMDA receptors from inhibition by memantine and ketamine reveal properties of a second site.

Authors:  Nathan G Glasgow; Madeleine R Wilcox; Jon W Johnson
Journal:  Neuropharmacology       Date:  2018-05-12       Impact factor: 5.250

5.  1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.

Authors:  Christa C Chrovian; Akinola Soyode-Johnson; Jessica L Wall; Jason C Rech; Jeff Schoellerman; Brian Lord; Kevin J Coe; Nicholas I Carruthers; Leslie Nguyen; Xiaohui Jiang; Tatiana Koudriakova; Bartosz Balana; Michael A Letavic
Journal:  ACS Med Chem Lett       Date:  2019-01-10       Impact factor: 4.345

6.  Memantine and Ketamine Differentially Alter NMDA Receptor Desensitization.

Authors:  Nathan G Glasgow; Nadezhda V Povysheva; Andrea M Azofeifa; Jon W Johnson
Journal:  J Neurosci       Date:  2017-09-06       Impact factor: 6.167

Review 7.  Recent insights into the mode of action of memantine and ketamine.

Authors:  Jon W Johnson; Nathan G Glasgow; Nadezhda V Povysheva
Journal:  Curr Opin Pharmacol       Date:  2014-12-02       Impact factor: 5.547

Review 8.  Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy.

Authors:  Caroline Caddy; Giovanni Giaroli; Thomas P White; Sukhwinder S Shergill; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2014-04

9.  NR2B Antagonist CP-101,606 Abolishes Pitch-Mediated Deviance Detection in Awake Rats.

Authors:  Digavalli V Sivarao; Ping Chen; Yili Yang; Yu-Wen Li; Rick Pieschl; Michael K Ahlijanian
Journal:  Front Psychiatry       Date:  2014-08-05       Impact factor: 4.157

10.  Ketamine Within Clinically Effective Range Inhibits Glutamate Transmission From Astrocytes to Neurons and Disrupts Synchronization of Astrocytic SICs.

Authors:  Yu Zhang; Sisi Wu; Liwei Xie; Shouyang Yu; Lin Zhang; Chengxi Liu; Wenjing Zhou; Tian Yu
Journal:  Front Cell Neurosci       Date:  2019-06-11       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.